The White House has withdrawn the nomination of Dr. Heidi Overton for Commissioner of the Food and Drug Administration, ending what had become an increasingly uncertain confirmation process just hours before a scheduled Senate committee vote.
The decision came Tuesday evening, according to senior administration officials and others with knowledge of the matter. The Senate Health, Education, Labor and Pensions Committee had been prepared to vote on the nomination Wednesday morning.
Dr. Overton, a physician who served on the White House domestic policy staff, had faced mounting difficulty securing support among Senate Republicans. Her testimony regarding the FDA-approved abortion drug mifepristone and her implementation of the administration’s vaping policies had drawn skepticism from key lawmakers and administration allies.
The withdrawal represents a significant setback for an agency that has operated without Senate-confirmed leadership since Dr. Marty Makary departed in May. The FDA regulates products accounting for approximately twenty percent of consumer spending in the United States, making stable leadership a matter of considerable economic and public health importance.
Senator Bill Cassidy of Louisiana, the outgoing chairman of the Senate HELP Committee, disputed characterizations that Dr. Overton lacked sufficient support for confirmation. In a statement late Tuesday, Senator Cassidy argued the White House had "abandoned a viable confirmation path."
According to Senator Cassidy, pro-life senators had sought final assurances from the administration regarding its commitment to life issues before the vote. Rather than provide those assurances, the administration chose to withdraw the nomination entirely.
"I believe she would have had the votes to pass out of committee and pass the full Senate," Senator Cassidy stated. "My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk."
The timing of the withdrawal adds complexity to the situation. With Democrats set to take control of the Senate in January, the window for confirming any Trump nominee has narrowed considerably. Senator Cassidy acknowledged that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."
The administration had reportedly begun considering alternative candidates for the position even before formally withdrawing Dr. Overton’s nomination. Some under consideration could serve in an acting capacity, thereby avoiding the need for Senate confirmation. The agency is currently led by Acting Commissioner Kyle Diamantas.
There are indications that Senator Roger Marshall of Kansas, a physician who recently lost his reelection bid, is seeking consideration for the FDA post. Any nominee requiring Senate confirmation would need to move through the process before the January transition of power.
Dr. Overton was nominated over the summer and was understood to have maintained close ties with former White House Chief of Staff Susie Wiles, who departed her position earlier this month. President Trump had selected Dr. Overton from within his own domestic policy team for the critical regulatory role.
The FDA commissioner position carries substantial authority over drug approvals, medical device regulations, and food safety standards. Senator Cassidy has expressed concern that a succession of acting administrators might prove more susceptible to pressure from the Secretary of Health and Human Services than a Senate-confirmed leader would be.
The question now facing the administration is whether to pursue confirmation of another nominee in the remaining weeks of Republican Senate control or to continue operating with acting leadership into the new year.
Related: Senate Republican Warns Social Security Operating as Legal Ponzi Scheme
